Alectinib is a highly selective, potent inhibitor of anaplastic lymphoma kinase (ALK). It is primarily used in the treatment of ALK-positive non-small cell lung cancer (NSCLC). Alectinib works by inhibiting the activity of ALK, a protein that promotes the growth of cancer cells.
